Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.78 USD | -1.70% | -5.59% | +244.28% |
Financials (USD)
Sales 2024 * | 2.14M | Sales 2025 * | - | Capitalization | 822M |
---|---|---|---|---|---|
Net income 2024 * | -66M | Net income 2025 * | -93M | EV / Sales 2024 * | 259 x |
Net cash position 2024 * | 267M | Net cash position 2025 * | 320M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-11.3
x | P/E ratio 2025 * |
-9.25
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.5% |
Latest transcript on Longboard Pharmaceuticals, Inc.
1 day | +3.88% | ||
1 week | -2.58% | ||
Current month | -0.75% | ||
1 month | +15.84% | ||
3 months | +1.44% | ||
6 months | +333.20% | ||
Current year | +250.58% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 20-01-02 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 20-12-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 20-11-30 |
Director/Board Member | 67 | 20-11-30 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.41% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +4.06% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 20.8 | -1.61% | 7 094 |
24-05-15 | 21.14 | +3.88% | 188,049 |
24-05-14 | 20.35 | +2.11% | 113,364 |
24-05-13 | 19.93 | -0.94% | 151,230 |
24-05-10 | 20.12 | -8.50% | 156,226 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+250.58% | 822M | |
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- LBPH Stock